BioFactura, Inc. publishes Phase 1 data on its Ustekinumab biosimilar
BioFactura, Inc. announced the publication of the phase 1 study for BFI-751, a biosimilar candidate to Stelara (ustekinumab) in the peer reviewed journal, Clinical Pharmacology in Drug Development FREDERICK, Md., Sept. 11, 2023 /PRNewswire-PRWeb/ -- BioFactura, Inc. announced the... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 11, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
The 10 Drugs Medicare Can Negotiate Were Just Announced. These Pharma Stocks Are Impacted
Eliquis, Jardiance, and Stelara are among the first of 10 different drugs that are now subject to Medicare price negotiations following the passing of the Inflation Reduction Act.#medicare (Source: Reuters: Health)
Source: Reuters: Health - August 29, 2023 Category: Consumer Health News Source Type: news
Biologics After Exposure to TNF Inhibitors in Ulcerative Colitis Biologics After Exposure to TNF Inhibitors in Ulcerative Colitis
This study assessed the real-world efficacy of vedolizumab, ustekinumab and tofacitinib as second-line therapies in patients with ulcerative colitis who were previously exposed to a TNF inhibitor.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 8, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Improvements After 3-Year Ustekinumab or TNFi PsA Treatment Improvements After 3-Year Ustekinumab or TNFi PsA Treatment
Did these therapies lead to outcome and productivity improvements among psoriatic arthritis patients? A new study evaluated the real-world effects.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 8, 2023 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Aurobindo Pharma subsidiary enters pact with BioFactura for biosimilar ustekinumab
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma said it has entered into an exclusive license agreement with the US-based BioFactura to commercialize BFI-751, a proposed biosimilar to Stelara (ustekinumab). Ustekinumab is used for treating Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 10, 2023 Category: Pharmaceuticals Source Type: news
Amgen Settles Patent Lawsuit Over Biosimilar of Stelara Amgen Settles Patent Lawsuit Over Biosimilar of Stelara
Johnson& Johnson has settled its lawsuit over Amgen ' s proposed biosimilar version of J&J ' s top-selling treatment Stelara for psoriasis and other autoimmune conditions, according to a filing in Delaware federal court.Reuters Health Information (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - May 25, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Johnson & Johnson Reports Q1 2023 Results
New Brunswick, N.J. (April 18, 2023) – Johnson & Johnson (NYSE: JNJ) today announced results for first-quarter 2023. “Our first quarter results demonstrate strong performance across all three segments of our business and reflect the dedication of Johnson & Johnson colleagues around the world,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “With this momentum, I look forward to the remainder of the year, one filled with exciting catalysts that will create both near- and long-term value for patients and all of our stakeholders.”OVERALL FINANCIAL RESULTSQ1($ in Millions, except EPS)2...
Source: Johnson and Johnson - April 18, 2023 Category: Pharmaceuticals Tags: Financial Source Type: news
Ustekinumab Effectiveness and Safety in Ulcerative Colitis Ustekinumab Effectiveness and Safety in Ulcerative Colitis
Does the effectiveness and safety of ustekinumab seen in clinical trials translate to real-world clinical outcomes?Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - March 23, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Biologics May Delay Arthritis in Psoriasis Patients Biologics May Delay Arthritis in Psoriasis Patients
Treatment with the interleukin-12/23 inhibitor ustekinumab or interleukin-23 inhibitors was linked to a lower risk of developing psoriatic arthritis compared with tumor necrosis factor inhibitors.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - March 9, 2023 Category: Dermatology Tags: Rheumatology News Source Type: news
New STELARA ® (ustekinumab) Long-Term Data Support its Established Safety Profile in Inflammatory Bowel Disease and Durable Efficacy in Ulcerative Colitis
SPRING HOUSE, PENNSYLVANIA, March 4, 2023 – The Janssen Pharmaceutical Companies of Johnson & Johnson today announced final pooled long-term safety results for STELARA® (ustekinumab) through five years in adults with moderately to severely active Crohn’s disease (CD) and four years in adults with moderately to severely active ulcerative colitis (UC), as well as final four-year clinical and endoscopic outcomes from the UNIFI long-term extension (LTE) study evaluating the efficacy of STELARA for the treatment of adults with moderately to severely active UC.1,2 These data are a part of Janssen’s 22 oral and poster ...
Source: Johnson and Johnson - March 4, 2023 Category: Pharmaceuticals Tags: Latest News Source Type: news
DNA Panels Could Predict Endoscopic Response to Biologics in CD DNA Panels Could Predict Endoscopic Response to Biologics in CD
Peripheral blood biomarkers in development that use DNA methylation could predict endoscopic response to treatment with adalimumab, vedolizumab, and ustekinumab for patients with Crohn ' s disease.Medscape Medical News (Source: Medscape Pharmacist Headlines)
Source: Medscape Pharmacist Headlines - March 4, 2023 Category: Drugs & Pharmacology Tags: Gastroenterology News Source Type: news
Pediatric Psoriasis: Infection Risk Low With Systemic Meds Pediatric Psoriasis: Infection Risk Low With Systemic Meds
The results are from a large cohort study that estimated the 6-month rate of infections among children with psoriasis who started treatment with ustekinumab, etanercept, or methotrexate.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - February 16, 2023 Category: Dermatology Tags: Dermatology News Source Type: news
Johnson & Johnson Reports Q4 and Full-Year 2022 Results
NEW BRUNSWICK, N.J. – January 24, 2023 – Johnson & Johnson (NYSE: JNJ) today announced results for fourth-quarter and full year 2022. “Our full year 2022 results reflect the continued strength and stability of our three business segments, despite macroeconomic challenges,” said Joaquin Duato, Chairman of the Board and Chief Executive Officer. “I am inspired by our employees who make a difference in the health and lives of people around the world every day. As we look ahead to 2023, Johnson & Johnson is well-positioned to drive near-term growth, while also investing strategically to deliver long-term value...
Source: Johnson and Johnson - January 24, 2023 Category: Pharmaceuticals Source Type: news
Ustekinumab Matches TNF Inhibitors for PsA in Real-World Study Ustekinumab Matches TNF Inhibitors for PsA in Real-World Study
A real-world study comparing the interleukin-12/23 inhibitor ustekinumab with tumor necrosis factor inhibitors for psoriatic arthritis found similar rates of treatment persistence and efficacy.MDedge News (Source: Medscape Dermatology Headlines)
Source: Medscape Dermatology Headlines - December 16, 2022 Category: Dermatology Tags: Rheumatology News Source Type: news
Is Pfizer Stock A Better Pick Over This Pharmaceuticals Bellwether?
We believe that Pfizer stock (NYSE: PFE) is currently a better pick than its peer, Johnson & Johnson stock (NYSE: JNJ), given its relatively lower valuation of 3.1x trailing revenues, compared to 4.9x for J&J. We think that this valuation gap should narrow, given Pfizer’s If we look at stock…#pfizers #peercomparisons #jjs #johnsonjohnsonoperatingincomecompa #stelara #pfizer #pfe #johnsonjohnson #darzalex #merck (Source: Reuters: Health)
Source: Reuters: Health - December 16, 2022 Category: Consumer Health News Source Type: news
